Table 5 Results in perspective (adapted from [24])
RAS blocking agent | Control | Number of patients | Follow-up | RR (95%CI) | |
|---|---|---|---|---|---|
SOLVD [36] | Enalapril | Placebo | 4,228 | 3.4 | 0.26 (0.13-0.53) |
AASK [30] | Ramipril | Betablocker/ Amlodipine | 1,094 | 4.1 | 0.64 (0.45-0.90) |
HOPE [31] | Ramipril | Placebo | 9,297 | 5 | 0.67 (0.52-0.85) |
Enalapril | Diuretic | 6,083 | 4.1 | 0.70 (0.56-0.86) | |
ALLHAT [39] | Lisinopril | Chlorthalidone/Amlodipine | 33,357 | 4.9 | 0.75 (0.59-0.94) |
IMAGINE [40] | Quinapril | Placebo | 2,553 | 2.95 | 0.79 (0.48-1.29) |
ADaPT [22] | Ramipril | Betablockers/ Diuretic | 2,011 | 3 | 0.83 (0.65-0.80) |
PEACE [41] | Trandolapril | Placebo | 8,290 | 4.8 | 0.85 (0.74-0.97) |
CAPPP [42] | Captopril | Betablockers/ Diuretic | 10,985 | 6.1 | 0.89 (0.78-1.03) |
Ramipril | Placebo | 5,269 | 3 | 0.93 (0.82-1.04) | |
STOP-2 [43] | Enalapril/ Lisinopril | Betablockers/ Diuretic | 6,614 | 5 | 0.95 (0.72-1.26) |
ALPINE [44] | Candesartan | HCTZ | 392 | 1 | 0.13 (0.02-0.99) |
CASE-J [45] | Candesartan | Amlodipine | 4,703 | 3.2 | 0.65 (0.44-0.98) |
LIFE [46] | Losartan | Atenolol | 9,193 | 4.8 | 0.75 (0.64-0.88) |
CHARM [47] | Candesartan | Placebo | 7,599 | 3.2 | 0.81 (0.66-0.99) |
SCOPE [48] | Candesartan | Placebo | 4,937 | 3.7 | 0.81 (0.62-1.06) |
VALUE [16] | Valsartan | Amlodipine | 15,245 | 4.2 | 0.81 (0.74-0.89) |
PRoFESS [49] | Telmisartan | Placebo | 20,332 | 2.5 | 0.83 (0.65-1.04) |
TRANSCEND [50] | Telmisartan | Placebo | 5,926 | 4.6 | 0.86 (0.72-1.02) |
NAVIGATOR [17] | Valsartan | Placeno | 9,306 | 5 | 0.86 (0.80-0.92) |